Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
27 févr. 2019 16h35 HE
|
Jounce Therapeutics, Inc.
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday,...
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
13 nov. 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for...